# A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With Diabetic Macular Edema (DME)

> **NCT07425522** · PHASE1 · RECRUITING · sponsor: **Genentech, Inc.** · enrollment: 93 (estimated)

## Conditions studied

- Diabetic Macular Edema

## Interventions

- **DRUG:** RO7823653
- **DRUG:** Faricimab

## Key facts

- **NCT ID:** NCT07425522
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-21
- **Primary completion:** 2028-11-17
- **Final completion:** 2028-11-17
- **Target enrollment:** 93 (ESTIMATED)
- **Last updated:** 2026-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07425522

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07425522, "A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With Diabetic Macular Edema (DME)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07425522. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*